Tag: arteriovenous malformations market forecast

Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

Arteriovenous Malformations Market Forecast: What Market Value Is Expected By 2030?

The market for arteriovenous malformations (AVMs) has demonstrated robust expansion lately, projected to increase from $3.1 billion in 2025 to $3.33 billion by 2026, reflecting a compound annual growth rate of 7.3%. Historically, this growth has been propelled by advancements in neuroimaging, heightened clinical recognition of AVM conditions, the proliferation of dedicated neurosurgical facilities, the integration of endovascular embolization procedures, and the overall expansion of neurological care services within hospitals.

The market for arteriovenous malformations is projected to experience substantial expansion over the coming years, reaching an estimated $4.37 billion by 2030 with a compound annual growth rate of 7.1%. This anticipated growth trajectory is underpinned by several key factors, including a heightened demand for precise diagnostic tools, increased financial commitments to neurovascular research, a broader acceptance of less invasive treatment modalities, a greater emphasis on tailoring treatment strategies to individual patients, and the growing availability of sophisticated interventional equipment. During this forecast period, significant trends are expected to shape the market landscape, such as the wider integration of cutting-edge neuroimaging diagnostics, a rise in the utilization of endovascular treatments that require minimal invasion, a stronger push towards early and precise diagnosis, the increasing implementation of collaborative, multidisciplinary treatment plans, and more robust methods for monitoring patient recovery after interventions.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21888&type=smp

#Arteriovenous Malformations Market Demand Drivers Creating New Revenue Opportunities

The expanding preference for less invasive interventions is poised to accelerate the expansion of the arteriovenous malformations market. These less invasive approaches involve surgical or therapeutic actions carried out through subtle incisions or catheter-based methods, aiming to minimize physical trauma, expedite recovery periods, and reduce the likelihood of complications. The heightened demand for such surgeries stems from their capacity to facilitate quicker recuperation, as they require smaller cuts, inflict less damage to the body’s tissues, and shorten the overall healing duration. Consequently, patients can resume their regular routines sooner when contrasted with conventional open surgeries, making this approach a more attractive option for both individuals seeking treatment and medical professionals providing care in the arteriovenous malformations market. Techniques like endovascular embolization, which leverage catheters and image guidance to control aberrant blood flow without resorting to open procedures, exemplify how arteriovenous malformations are amenable to less invasive strategies, leading to diminished risks, shorter recovery times, and improved patient outcomes, as evidenced by a 7% rise in minimally invasive cosmetic procedures in the US during 2023, totaling 25,442,640.

Heightened financial commitments within the biotechnology sector are anticipated to be a significant catalyst for the expansion of the arteriovenous malformations market. Biotechnology, in essence, involves the utilization of biological systems, organisms, or processes to create novel healthcare products and technologies. This surge in biotechnology investment is largely attributable to groundbreaking advancements, particularly in gene editing technologies like CRISPR, which facilitate highly accurate genetic alterations that translate into medical innovations. The field of arteriovenous malformations is intrinsically linked to biotechnology through enhancements in medical imaging capabilities, progress in gene therapy applications, and the development of more delicate, minimally invasive treatment modalities, all contributing to sophisticated solutions such as precisely delivered pharmaceuticals, biocompatible materials for repairing blood vessels, and diagnostic tools augmented by artificial intelligence. Illustrating this trend, the UK’s vibrant life sciences and biotechnology industry attracted substantial investment, securing $2.55 billion in the initial half of 2024, thereby exceeding the $2.32 billion total for the entirety of 2023, underscoring the robust growth driven by escalating biotechnology investments within the arteriovenous malformations market.

Arteriovenous Malformations Market Segment Analysis Highlighting Growth Areas

The arteriovenous malformations market covered in this report is segmented –

1) By Type: True Arteriovenous Malformation, Occult Or Cryptic, Cavernous Malformations, Venous Malformation, Hemangioma, Dural Fistula, Other Types

2) By Diagnosis: Physical examination, Brain Scans, Other Diagnosis

3) By Treatment: Endovascular Embolization, Neurosurgery

4) By Age Group: Adult Patients, Pediatric Patients

5) By End-User: Hospitals And Clinics, Research laboratories, Other End-Users

Subsegments:

1) By True Arteriovenous Malformation: Pial AVMs, Spinal AVMs, Brain AVMs, Extremity AVMs, Visceral AVMs

2) By Occult or Cryptic: Micro-AVMs, Hidden AVMs, Asymptomatic AVMs, Deep-Seated AVMs, Small-Scale AVMs

3) By Cavernous Malformations: Cerebral Cavernous Malformations (CCMs), Spinal Cavernous Malformations, Familial Cavernous Malformations, Solitary Cavernous Malformations, Multiple Cavernous Malformations

4) By Venous Malformation: Superficial Venous Malformations, Deep Venous Malformations, Mixed Venous Malformations, Syndromic Venous Malformations, Blue Rubber Bleb Nevus Syndrome

5) By Hemangioma: Infantile Hemangiomas, Capillary Hemangiomas, Lobular Capillary Hemangiomas, Cavernous Hemangiomas, Compound Hemangiomas

6) By Dural Fistula: Cranial Dural Arteriovenous Fistula (dAVF), Spinal Dural Arteriovenous Fistula, Direct Dural AV Fistula, Indirect Dural AV Fistula, High-Flow Dural Fistula

7) By Other Types: Lymphatic Malformations, Mixed Vascular Malformations, Arteriovenous Aneurysms, Hereditary Hemorrhagic Telangiectasia (HHT)-Associated AVMs, Rare Congenital AVMs

Arteriovenous Malformations Market Trends Driving Strategic Industry Expansion

In the arteriovenous malformations market, leading corporations are prioritizing innovation, particularly in the development of liquid embolic system procedural sets, with the aim of simplifying treatment processes and enhancing patient results. Such a procedural set is essentially a fully assembled, sterile package containing all the vital items needed for administering liquid embolic agents to address conditions like arteriovenous malformations (AVMs). A prime illustration of this trend is the introduction in March 2024 by CERENOVUS Inc., a US entity specializing in neurovascular care and part of Johnson and Johnson MedTech, of its TRUFILL n-BCA liquid embolic system procedural set. This recently released set offers two distinct configurations alongside all required accessories, conveniently packaged together in a sterile unit to facilitate the preparation and deployment of the n-BCA liquid embolic system for the treatment of cerebral arteriovenous malformations (AVMs), thereby streamlining the pre-procedural workflow.

Arteriovenous Malformations Market Leading Companies: Who Holds Significant Market Presence?

Major companies operating in the arteriovenous malformations market are Johnson And Johnson Services Inc, Medtronic Plc, Stryker Corporation, Terumo Corporation, Penumbra Inc, Cook Medical LLC, Elekta AB, Merit Medical Systems Inc, Balt LLC, Shape Memory Medical Inc, MicroVention Inc, Cerenovus, Brainlab AG, Boston Scientific Corporation, Abbott Laboratories, B Braun Melsungen AG, Siemens Healthineers AG, GE Healthcare Technologies Inc, Koninklijke Philips NV, Canon Medical Systems Corporation, Toshiba Medical Systems Corporation

Access The Complete Arteriovenous Malformations Market Report:

https://www.thebusinessresearchcompany.com/report/arteriovenous-malformations-global-market-report

Arteriovenous Malformations Market Regional Analysis: Which Region Leads By Revenue?

North Americawas the largest region in the arteriovenous malformations market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the arteriovenous malformations market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Will The Market Value Of The Arteriovenous Malformations Market Increase Between 2026 And 2030?

The arteriovenous malformations market size has demonstrated significant expansion in recent years. It is anticipated to increase from $3.1 billion in 2025 to $3.33 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.3%. The market’s past growth is attributable to enhancements in neuroimaging technologies, heightened clinical awareness of avm conditions, the proliferation of specialized neurosurgical centers, the adoption of endovascular embolization techniques, and the expansion of hospital-based neurological care.

The market for arteriovenous malformations is projected to experience robust expansion over the coming years. This market is anticipated to reach a valuation of $4.37 billion by 2030, driven by a compound annual growth rate (CAGR) of 7.1%. Several factors are expected to fuel this growth during the projection period, including a heightened need for accurate diagnostics, greater financial input into neurovascular studies, a wider embrace of minimally invasive treatments, a stronger emphasis on individualized treatment strategies, and a broader supply of sophisticated interventional tools. Key developments expected within this timeframe involve a greater uptake of cutting-edge neuroimaging diagnostic methods, an increased application of minimally invasive endovascular therapies, a heightened priority on timely and precise diagnosis, the broadening of diverse treatment methodologies, and improved oversight of patient results after treatment.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21888&type=smp

What Major Growth Factors Are Impacting The Arteriovenous Malformations Market?

The arteriovenous malformations market is expected to grow, driven by the increasing preference for minimally invasive procedures. These surgical or therapeutic methods employ small incisions or catheter-based approaches to minimize trauma, shorten recovery periods, and reduce complications. The rising demand for these procedures is linked to their faster recovery times, as smaller incisions cause less tissue damage and accelerate healing. This allows patients to return to their daily routines more quickly compared to traditional open surgeries, making them a favored option for both patients and healthcare providers. Arteriovenous malformations (AVMs) benefit from minimally invasive techniques, such as endovascular embolization, which utilizes catheters and image-guided interventions to correct abnormal blood flow without requiring open surgery, thereby lowering risks, reducing recovery times, and improving patient outcomes. For example, data from the American Society of Plastic Surgeons in September 2023 showed that 25,442,640 cosmetic minimally invasive procedures were performed in the US in 2023, an increase from 23,672,269 procedures in 2022, signifying a 7% growth in minimally invasive treatments across both genders in 2023. Consequently, the growing demand for minimally invasive procedures is fueling the expansion of the arteriovenous malformations market.

Arteriovenous Malformations Market Driver: Increasing Investment In Biotechnology Fueling The Growth Of The Market Due To Advancements In Arteriovenous Malformations Treatment And Neurovascular Innovations

What Key Segment Areas Are Included In The Arteriovenous Malformations Market Assessment?

The arteriovenous malformations market covered in this report is segmented –

1) By Type: True Arteriovenous Malformation, Occult Or Cryptic, Cavernous Malformations, Venous Malformation, Hemangioma, Dural Fistula, Other Types

2) By Diagnosis: Physical examination, Brain Scans, Other Diagnosis

3) By Treatment: Endovascular Embolization, Neurosurgery

4) By Age Group: Adult Patients, Pediatric Patients

5) By End-User: Hospitals And Clinics, Research laboratories, Other End-Users

Subsegments:

1) By True Arteriovenous Malformation: Pial AVMs, Spinal AVMs, Brain AVMs, Extremity AVMs, Visceral AVMs

2) By Occult or Cryptic: Micro-AVMs, Hidden AVMs, Asymptomatic AVMs, Deep-Seated AVMs, Small-Scale AVMs

3) By Cavernous Malformations: Cerebral Cavernous Malformations (CCMs), Spinal Cavernous Malformations, Familial Cavernous Malformations, Solitary Cavernous Malformations, Multiple Cavernous Malformations

4) By Venous Malformation: Superficial Venous Malformations, Deep Venous Malformations, Mixed Venous Malformations, Syndromic Venous Malformations, Blue Rubber Bleb Nevus Syndrome

5) By Hemangioma: Infantile Hemangiomas, Capillary Hemangiomas, Lobular Capillary Hemangiomas, Cavernous Hemangiomas, Compound Hemangiomas

6) By Dural Fistula: Cranial Dural Arteriovenous Fistula (dAVF), Spinal Dural Arteriovenous Fistula, Direct Dural AV Fistula, Indirect Dural AV Fistula, High-Flow Dural Fistula

7) By Other Types: Lymphatic Malformations, Mixed Vascular Malformations, Arteriovenous Aneurysms, Hereditary Hemorrhagic Telangiectasia (HHT)-Associated AVMs, Rare Congenital AVMs

Which Trends Are Contributing To Changes In The Arteriovenous Malformations Market?

Major companies in the arteriovenous malformations market are concentrating on technological innovations, such as liquid embolic system procedural sets, to improve treatment procedures and patient outcomes. A liquid embolic system procedural set is a pre-assembled, sterilized kit containing essential components for delivering liquid embolic agents to treat vascular abnormalities like arteriovenous malformations (AVMs). For instance, in March 2024, CERENOVUS Inc., a US-based neurovascular care company under Johnson and Johnson MedTech, introduced the TRUFILL n-BCA liquid embolic system procedural set. This new set features two configurations and the necessary accessories for preparing and delivering the n-BCA liquid embolic system in a single sterilized package, optimizing procedure preparation for treating cerebral arteriovenous malformations (AVMs).

Who Are The Prominent Players Across The Arteriovenous Malformations Market?

Major companies operating in the arteriovenous malformations market are Johnson And Johnson Services Inc, Medtronic Plc, Stryker Corporation, Terumo Corporation, Penumbra Inc, Cook Medical LLC, Elekta AB, Merit Medical Systems Inc, Balt LLC, Shape Memory Medical Inc, MicroVention Inc, Cerenovus, Brainlab AG, Boston Scientific Corporation, Abbott Laboratories, B Braun Melsungen AG, Siemens Healthineers AG, GE Healthcare Technologies Inc, Koninklijke Philips NV, Canon Medical Systems Corporation, Toshiba Medical Systems Corporation

Access The Complete Arteriovenous Malformations Market Report:

https://www.thebusinessresearchcompany.com/report/arteriovenous-malformations-global-market-report

Which Region Commands The Largest Share Of The Arteriovenous Malformations Market?

North America was the largest region in the arteriovenous malformations market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the arteriovenous malformations market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Arteriovenous Malformations Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=21888&type=smp

Browse Through More Reports Similar to the Global Arteriovenous Malformations Market 2026, By The Business Research Company

Vascular Imaging Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/vascular-imaging-global-market-report

Giant Cell Arteritis Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/giant-cell-arteritis-global-market-report

Vascular Stent Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/vascular-stent-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Much Growth In Market Value Is Expected For The Arteriovenous Malformations Market Between 2026 And 2030?

The arteriovenous malformations market has experienced robust expansion in recent years. Its valuation is projected to rise from $3.1 billion in 2025 to $3.33 billion in 2026, reflecting a compound annual growth rate (CAGR) of 7.3%. Historically, this growth can be attributed to various elements such as enhancements in neuroimaging technologies, heightened clinical understanding of avm conditions, the establishment of more specialized neurosurgical centers, the implementation of endovascular embolization techniques, and the overall development of hospital-based neurological care.

The arteriovenous malformations market is poised for significant expansion in the coming years. Its value is projected to reach $4.37 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.1%. This anticipated growth during the forecast period is propelled by factors such as an escalating demand for precision diagnostics, increased investments in neurovascular research, the broadened adoption of minimally invasive treatments, a heightened focus on personalized treatment planning, and the growing availability of advanced interventional devices. Prominent trends observed within this period are expected to include the rising uptake of advanced neuroimaging diagnostics, an increased application of minimally invasive endovascular treatments, a stronger emphasis on early and accurate diagnosis, the expansion of multidisciplinary treatment approaches, and enhanced monitoring of post-treatment outcomes.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/arteriovenous-malformations-global-market-report

What Major Factors Are Driving The Arteriovenous Malformations Market Forward?

The increasing preference for minimally invasive procedures is anticipated to fuel the expansion of the arteriovenous malformations market in the future. These interventions involve surgical or therapeutic methods using small incisions or catheter-based approaches to minimize trauma, shorten recovery periods, and reduce complications. The growing appeal of minimally invasive surgeries stems from their ability to offer quicker recovery times, as smaller incisions result in less tissue damage and faster healing. This enables patients to resume their regular routines more swiftly compared to conventional open surgeries, making them a favored option for both patients and healthcare providers. Arteriovenous malformations (AVMs) are compatible with minimally invasive techniques, facilitating advanced methods like endovascular embolization, which employs catheters and image guidance to diminish abnormal blood flow without the necessity for open surgery, thereby leading to reduced risks, shorter recovery, and enhanced patient results. For instance, data from September 2023, provided by the American Society of Plastic Surgeons, a US-based organization, indicated that 25,442,640 cosmetic minimally invasive procedures were carried out in 2023, marking an increase from 23,672,269 procedures in 2022. This demonstrates a 7% rise in minimally invasive treatments for both genders in 2023. Consequently, the escalating demand for minimally invasive procedures is propelling the growth of the arteriovenous malformations market.

Which Segment Classifications Are Used In The Arteriovenous Malformations Market Segment Analysis?

The arteriovenous malformations market covered in this report is segmented –

1) By Type: True Arteriovenous Malformation, Occult Or Cryptic, Cavernous Malformations, Venous Malformation, Hemangioma, Dural Fistula, Other Types

2) By Diagnosis: Physical examination, Brain Scans, Other Diagnosis

3) By Treatment: Endovascular Embolization, Neurosurgery

4) By Age Group: Adult Patients, Pediatric Patients

5) By End-User: Hospitals And Clinics, Research laboratories, Other End-Users

Subsegments:

1) By True Arteriovenous Malformation: Pial AVMs, Spinal AVMs, Brain AVMs, Extremity AVMs, Visceral AVMs

2) By Occult or Cryptic: Micro-AVMs, Hidden AVMs, Asymptomatic AVMs, Deep-Seated AVMs, Small-Scale AVMs

3) By Cavernous Malformations: Cerebral Cavernous Malformations (CCMs), Spinal Cavernous Malformations, Familial Cavernous Malformations, Solitary Cavernous Malformations, Multiple Cavernous Malformations

4) By Venous Malformation: Superficial Venous Malformations, Deep Venous Malformations, Mixed Venous Malformations, Syndromic Venous Malformations, Blue Rubber Bleb Nevus Syndrome

5) By Hemangioma: Infantile Hemangiomas, Capillary Hemangiomas, Lobular Capillary Hemangiomas, Cavernous Hemangiomas, Compound Hemangiomas

6) By Dural Fistula: Cranial Dural Arteriovenous Fistula (dAVF), Spinal Dural Arteriovenous Fistula, Direct Dural AV Fistula, Indirect Dural AV Fistula, High-Flow Dural Fistula

7) By Other Types: Lymphatic Malformations, Mixed Vascular Malformations, Arteriovenous Aneurysms, Hereditary Hemorrhagic Telangiectasia (HHT)-Associated AVMs, Rare Congenital AVMs

Which Trends Are Impacting The Progress Of The Arteriovenous Malformations Market?

Leading companies in the arteriovenous malformations market are concentrating on technological advancements, such as liquid embolic system procedural sets, to improve treatment efficiency and patient outcomes. A liquid embolic system procedural set refers to a pre-assembled, sterilized kit containing crucial components for delivering liquid embolic agents to address vascular abnormalities like arteriovenous malformations (AVMs). For instance, in March 2024, CERENOVUS Inc., a US-based neurovascular care company under Johnson and Johnson MedTech, introduced the TRUFILL n-BCA liquid embolic system procedural set. This new set comprises two configurations and the necessary accessories for preparing and delivering the n-BCA liquid embolic system in a single sterilized package, streamlining procedure preparation for treating cerebral arteriovenous malformations (AVMs).

Which Firms Are Contributing To The Arteriovenous Malformations Market Ecosystem?

Major companies operating in the arteriovenous malformations market are Johnson And Johnson Services Inc, Medtronic Plc, Stryker Corporation, Terumo Corporation, Penumbra Inc, Cook Medical LLC, Elekta AB, Merit Medical Systems Inc, Balt LLC, Shape Memory Medical Inc, MicroVention Inc, Cerenovus, Brainlab AG, Boston Scientific Corporation, Abbott Laboratories, B Braun Melsungen AG, Siemens Healthineers AG, GE Healthcare Technologies Inc, Koninklijke Philips NV, Canon Medical Systems Corporation, Toshiba Medical Systems Corporation

Get The Full Arteriovenous Malformations Market Report:

https://www.thebusinessresearchcompany.com/report/arteriovenous-malformations-global-market-report

Which Region Is The Top Contributor To The Arteriovenous Malformations Market By Share?

North America was the largest region in the arteriovenous malformations market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the arteriovenous malformations market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Arteriovenous Malformations Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/arteriovenous-malformations-global-market-report

Browse Through More Reports Similar to the Global Arteriovenous Malformations Market 2026, By The Business Research Company

Vascular Stent Market Report 2026

https://www.thebusinessresearchcompany.com/report/vascular-stent-global-market-report

Vascular Imaging Market Report 2026

https://www.thebusinessresearchcompany.com/report/vascular-imaging-global-market-report

Giant Cell Arteritis Market Report 2026

https://www.thebusinessresearchcompany.com/report/giant-cell-arteritis-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Much Growth In Market Value Is Expected For The Arteriovenous Malformations Market Between 2026 And 2030?

The arteriovenous malformations market has experienced robust expansion in recent years. Its valuation is projected to rise from $3.1 billion in 2025 to $3.33 billion in 2026, reflecting a compound annual growth rate (CAGR) of 7.3%. Historically, this growth can be attributed to various elements such as enhancements in neuroimaging technologies, heightened clinical understanding of avm conditions, the establishment of more specialized neurosurgical centers, the implementation of endovascular embolization techniques, and the overall development of hospital-based neurological care.

The arteriovenous malformations market is poised for significant expansion in the coming years. Its value is projected to reach $4.37 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.1%. This anticipated growth during the forecast period is propelled by factors such as an escalating demand for precision diagnostics, increased investments in neurovascular research, the broadened adoption of minimally invasive treatments, a heightened focus on personalized treatment planning, and the growing availability of advanced interventional devices. Prominent trends observed within this period are expected to include the rising uptake of advanced neuroimaging diagnostics, an increased application of minimally invasive endovascular treatments, a stronger emphasis on early and accurate diagnosis, the expansion of multidisciplinary treatment approaches, and enhanced monitoring of post-treatment outcomes.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/arteriovenous-malformations-global-market-report

What Major Factors Are Driving The Arteriovenous Malformations Market Forward?

The increasing preference for minimally invasive procedures is anticipated to fuel the expansion of the arteriovenous malformations market in the future. These interventions involve surgical or therapeutic methods using small incisions or catheter-based approaches to minimize trauma, shorten recovery periods, and reduce complications. The growing appeal of minimally invasive surgeries stems from their ability to offer quicker recovery times, as smaller incisions result in less tissue damage and faster healing. This enables patients to resume their regular routines more swiftly compared to conventional open surgeries, making them a favored option for both patients and healthcare providers. Arteriovenous malformations (AVMs) are compatible with minimally invasive techniques, facilitating advanced methods like endovascular embolization, which employs catheters and image guidance to diminish abnormal blood flow without the necessity for open surgery, thereby leading to reduced risks, shorter recovery, and enhanced patient results. For instance, data from September 2023, provided by the American Society of Plastic Surgeons, a US-based organization, indicated that 25,442,640 cosmetic minimally invasive procedures were carried out in 2023, marking an increase from 23,672,269 procedures in 2022. This demonstrates a 7% rise in minimally invasive treatments for both genders in 2023. Consequently, the escalating demand for minimally invasive procedures is propelling the growth of the arteriovenous malformations market.

Which Segment Classifications Are Used In The Arteriovenous Malformations Market Segment Analysis?

The arteriovenous malformations market covered in this report is segmented –

1) By Type: True Arteriovenous Malformation, Occult Or Cryptic, Cavernous Malformations, Venous Malformation, Hemangioma, Dural Fistula, Other Types

2) By Diagnosis: Physical examination, Brain Scans, Other Diagnosis

3) By Treatment: Endovascular Embolization, Neurosurgery

4) By Age Group: Adult Patients, Pediatric Patients

5) By End-User: Hospitals And Clinics, Research laboratories, Other End-Users

Subsegments:

1) By True Arteriovenous Malformation: Pial AVMs, Spinal AVMs, Brain AVMs, Extremity AVMs, Visceral AVMs

2) By Occult or Cryptic: Micro-AVMs, Hidden AVMs, Asymptomatic AVMs, Deep-Seated AVMs, Small-Scale AVMs

3) By Cavernous Malformations: Cerebral Cavernous Malformations (CCMs), Spinal Cavernous Malformations, Familial Cavernous Malformations, Solitary Cavernous Malformations, Multiple Cavernous Malformations

4) By Venous Malformation: Superficial Venous Malformations, Deep Venous Malformations, Mixed Venous Malformations, Syndromic Venous Malformations, Blue Rubber Bleb Nevus Syndrome

5) By Hemangioma: Infantile Hemangiomas, Capillary Hemangiomas, Lobular Capillary Hemangiomas, Cavernous Hemangiomas, Compound Hemangiomas

6) By Dural Fistula: Cranial Dural Arteriovenous Fistula (dAVF), Spinal Dural Arteriovenous Fistula, Direct Dural AV Fistula, Indirect Dural AV Fistula, High-Flow Dural Fistula

7) By Other Types: Lymphatic Malformations, Mixed Vascular Malformations, Arteriovenous Aneurysms, Hereditary Hemorrhagic Telangiectasia (HHT)-Associated AVMs, Rare Congenital AVMs

Which Trends Are Impacting The Progress Of The Arteriovenous Malformations Market?

Leading companies in the arteriovenous malformations market are concentrating on technological advancements, such as liquid embolic system procedural sets, to improve treatment efficiency and patient outcomes. A liquid embolic system procedural set refers to a pre-assembled, sterilized kit containing crucial components for delivering liquid embolic agents to address vascular abnormalities like arteriovenous malformations (AVMs). For instance, in March 2024, CERENOVUS Inc., a US-based neurovascular care company under Johnson and Johnson MedTech, introduced the TRUFILL n-BCA liquid embolic system procedural set. This new set comprises two configurations and the necessary accessories for preparing and delivering the n-BCA liquid embolic system in a single sterilized package, streamlining procedure preparation for treating cerebral arteriovenous malformations (AVMs).

Which Firms Are Contributing To The Arteriovenous Malformations Market Ecosystem?

Major companies operating in the arteriovenous malformations market are Johnson And Johnson Services Inc, Medtronic Plc, Stryker Corporation, Terumo Corporation, Penumbra Inc, Cook Medical LLC, Elekta AB, Merit Medical Systems Inc, Balt LLC, Shape Memory Medical Inc, MicroVention Inc, Cerenovus, Brainlab AG, Boston Scientific Corporation, Abbott Laboratories, B Braun Melsungen AG, Siemens Healthineers AG, GE Healthcare Technologies Inc, Koninklijke Philips NV, Canon Medical Systems Corporation, Toshiba Medical Systems Corporation

Get The Full Arteriovenous Malformations Market Report:

https://www.thebusinessresearchcompany.com/report/arteriovenous-malformations-global-market-report

Which Region Is The Top Contributor To The Arteriovenous Malformations Market By Share?

North America was the largest region in the arteriovenous malformations market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the arteriovenous malformations market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Arteriovenous Malformations Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/arteriovenous-malformations-global-market-report

Browse Through More Reports Similar to the Global Arteriovenous Malformations Market 2026, By The Business Research Company

Vascular Stent Market Report 2026

https://www.thebusinessresearchcompany.com/report/vascular-stent-global-market-report

Vascular Imaging Market Report 2026

https://www.thebusinessresearchcompany.com/report/vascular-imaging-global-market-report

Giant Cell Arteritis Market Report 2026

https://www.thebusinessresearchcompany.com/report/giant-cell-arteritis-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Much Growth In Market Value Is Expected For The Arteriovenous Malformations Market Between 2026 And 2030?

The arteriovenous malformations market has experienced robust expansion in recent years. Its valuation is projected to rise from $3.1 billion in 2025 to $3.33 billion in 2026, reflecting a compound annual growth rate (CAGR) of 7.3%. Historically, this growth can be attributed to various elements such as enhancements in neuroimaging technologies, heightened clinical understanding of avm conditions, the establishment of more specialized neurosurgical centers, the implementation of endovascular embolization techniques, and the overall development of hospital-based neurological care.

The arteriovenous malformations market is poised for significant expansion in the coming years. Its value is projected to reach $4.37 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.1%. This anticipated growth during the forecast period is propelled by factors such as an escalating demand for precision diagnostics, increased investments in neurovascular research, the broadened adoption of minimally invasive treatments, a heightened focus on personalized treatment planning, and the growing availability of advanced interventional devices. Prominent trends observed within this period are expected to include the rising uptake of advanced neuroimaging diagnostics, an increased application of minimally invasive endovascular treatments, a stronger emphasis on early and accurate diagnosis, the expansion of multidisciplinary treatment approaches, and enhanced monitoring of post-treatment outcomes.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/arteriovenous-malformations-global-market-report

What Major Factors Are Driving The Arteriovenous Malformations Market Forward?

The increasing preference for minimally invasive procedures is anticipated to fuel the expansion of the arteriovenous malformations market in the future. These interventions involve surgical or therapeutic methods using small incisions or catheter-based approaches to minimize trauma, shorten recovery periods, and reduce complications. The growing appeal of minimally invasive surgeries stems from their ability to offer quicker recovery times, as smaller incisions result in less tissue damage and faster healing. This enables patients to resume their regular routines more swiftly compared to conventional open surgeries, making them a favored option for both patients and healthcare providers. Arteriovenous malformations (AVMs) are compatible with minimally invasive techniques, facilitating advanced methods like endovascular embolization, which employs catheters and image guidance to diminish abnormal blood flow without the necessity for open surgery, thereby leading to reduced risks, shorter recovery, and enhanced patient results. For instance, data from September 2023, provided by the American Society of Plastic Surgeons, a US-based organization, indicated that 25,442,640 cosmetic minimally invasive procedures were carried out in 2023, marking an increase from 23,672,269 procedures in 2022. This demonstrates a 7% rise in minimally invasive treatments for both genders in 2023. Consequently, the escalating demand for minimally invasive procedures is propelling the growth of the arteriovenous malformations market.

Which Segment Classifications Are Used In The Arteriovenous Malformations Market Segment Analysis?

The arteriovenous malformations market covered in this report is segmented –

1) By Type: True Arteriovenous Malformation, Occult Or Cryptic, Cavernous Malformations, Venous Malformation, Hemangioma, Dural Fistula, Other Types

2) By Diagnosis: Physical examination, Brain Scans, Other Diagnosis

3) By Treatment: Endovascular Embolization, Neurosurgery

4) By Age Group: Adult Patients, Pediatric Patients

5) By End-User: Hospitals And Clinics, Research laboratories, Other End-Users

Subsegments:

1) By True Arteriovenous Malformation: Pial AVMs, Spinal AVMs, Brain AVMs, Extremity AVMs, Visceral AVMs

2) By Occult or Cryptic: Micro-AVMs, Hidden AVMs, Asymptomatic AVMs, Deep-Seated AVMs, Small-Scale AVMs

3) By Cavernous Malformations: Cerebral Cavernous Malformations (CCMs), Spinal Cavernous Malformations, Familial Cavernous Malformations, Solitary Cavernous Malformations, Multiple Cavernous Malformations

4) By Venous Malformation: Superficial Venous Malformations, Deep Venous Malformations, Mixed Venous Malformations, Syndromic Venous Malformations, Blue Rubber Bleb Nevus Syndrome

5) By Hemangioma: Infantile Hemangiomas, Capillary Hemangiomas, Lobular Capillary Hemangiomas, Cavernous Hemangiomas, Compound Hemangiomas

6) By Dural Fistula: Cranial Dural Arteriovenous Fistula (dAVF), Spinal Dural Arteriovenous Fistula, Direct Dural AV Fistula, Indirect Dural AV Fistula, High-Flow Dural Fistula

7) By Other Types: Lymphatic Malformations, Mixed Vascular Malformations, Arteriovenous Aneurysms, Hereditary Hemorrhagic Telangiectasia (HHT)-Associated AVMs, Rare Congenital AVMs

Which Trends Are Impacting The Progress Of The Arteriovenous Malformations Market?

Leading companies in the arteriovenous malformations market are concentrating on technological advancements, such as liquid embolic system procedural sets, to improve treatment efficiency and patient outcomes. A liquid embolic system procedural set refers to a pre-assembled, sterilized kit containing crucial components for delivering liquid embolic agents to address vascular abnormalities like arteriovenous malformations (AVMs). For instance, in March 2024, CERENOVUS Inc., a US-based neurovascular care company under Johnson and Johnson MedTech, introduced the TRUFILL n-BCA liquid embolic system procedural set. This new set comprises two configurations and the necessary accessories for preparing and delivering the n-BCA liquid embolic system in a single sterilized package, streamlining procedure preparation for treating cerebral arteriovenous malformations (AVMs).

Which Firms Are Contributing To The Arteriovenous Malformations Market Ecosystem?

Major companies operating in the arteriovenous malformations market are Johnson And Johnson Services Inc, Medtronic Plc, Stryker Corporation, Terumo Corporation, Penumbra Inc, Cook Medical LLC, Elekta AB, Merit Medical Systems Inc, Balt LLC, Shape Memory Medical Inc, MicroVention Inc, Cerenovus, Brainlab AG, Boston Scientific Corporation, Abbott Laboratories, B Braun Melsungen AG, Siemens Healthineers AG, GE Healthcare Technologies Inc, Koninklijke Philips NV, Canon Medical Systems Corporation, Toshiba Medical Systems Corporation

Get The Full Arteriovenous Malformations Market Report:

https://www.thebusinessresearchcompany.com/report/arteriovenous-malformations-global-market-report

Which Region Is The Top Contributor To The Arteriovenous Malformations Market By Share?

North America was the largest region in the arteriovenous malformations market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the arteriovenous malformations market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Arteriovenous Malformations Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/arteriovenous-malformations-global-market-report

Browse Through More Reports Similar to the Global Arteriovenous Malformations Market 2026, By The Business Research Company

Vascular Stent Market Report 2026

https://www.thebusinessresearchcompany.com/report/vascular-stent-global-market-report

Vascular Imaging Market Report 2026

https://www.thebusinessresearchcompany.com/report/vascular-imaging-global-market-report

Giant Cell Arteritis Market Report 2026

https://www.thebusinessresearchcompany.com/report/giant-cell-arteritis-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Anticipated For The Arteriovenous Malformations Market Over The Period 2026–2030?

The arteriovenous malformations market has witnessed significant expansion in recent times. Its value is forecast to climb from $3.1 billion in 2025 to $3.33 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.3%. This historical upward trend is attributable to breakthroughs in neuroimaging technologies, heightened clinical recognition of AVM conditions, the establishment of more specialized neurosurgical centers, the adoption of endovascular embolization methods, and the growth of neurological services in hospitals.

The arteriovenous malformations market size is anticipated to experience robust expansion over the coming years. It is projected to achieve a value of $4.37 billion by 2030, progressing at a compound annual growth rate (CAGR) of 7.1%. This projected growth throughout the forecast period primarily stems from an escalating demand for accurate diagnostics, increased investments in neurovascular research, a broader embrace of minimally invasive treatments, an intensified focus on customized treatment strategies, and the greater availability of sophisticated interventional devices. Significant patterns expected during this period encompass the growing integration of advanced neuroimaging diagnostics, an increase in the application of minimally invasive endovascular procedures, a heightened emphasis on prompt and precise diagnosis, the broadening of interdisciplinary treatment methodologies, and improved oversight of patient outcomes following treatment.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21888&type=smp

What Drivers Are Expected To Influence The Arteriovenous Malformations Market During The Forecast Period?

The growing demand for minimally invasive procedures is anticipated to propel the arteriovenous malformations market forward. Minimally invasive procedures encompass surgical or therapeutic interventions performed through small incisions or catheter-based methods, aiming to reduce trauma, shorten recovery periods, and lower complications. The increasing preference for these surgeries stems from their quicker recovery times, as smaller incisions cause less tissue damage and accelerate healing. This enables patients to return to their daily routines more rapidly compared to conventional open surgeries, making them a favored option for both patients and healthcare providers. Arteriovenous malformations (AVMs) are well-suited for minimally invasive procedures by allowing advanced techniques such as endovascular embolization, which employs catheters and image-guided interventions to alleviate abnormal blood flow without the necessity of open surgery, leading to reduced risks, shorter recovery times, and improved patient outcomes. For instance, in September 2023, data from the American Society of Plastic Surgeons showed that a total of 25,442,640 cosmetic minimally invasive procedures were performed in the US in 2023, indicating an increase from 23,672,269 procedures in 2022. This reflects a 7% growth in minimally invasive treatments for both genders in 2023. Consequently, the rising demand for minimally invasive procedures is driving the expansion of the arteriovenous malformations market. The increasing investment in biotechnology is projected to stimulate the growth of the arteriovenous malformations market going forward. Biotechnology involves the utilization of biological processes, organisms, or systems to develop products and technologies for healthcare. Enhanced investments in biotechnology are a result of breakthroughs in gene editing technologies like CRISPR, which facilitate precise genetic modifications alongside innovations in medicine. Arteriovenous malformations (AVMs) benefit from biotechnology through advancements in medical imaging, gene therapy, and minimally invasive treatments, leading to biotechnology-derived solutions such as targeted drug delivery, biomaterials for vascular repair, and AI-assisted diagnostics. For instance, in August 2024, according to The BioIndustry Association (BIA), the UK’s life sciences and biotechnology sector recorded its most substantial investment quarter since the pandemic in 2024, securing $2.55 billion in the first two quarters of the year and surpassing the $2.32 billion raised in 2023. Therefore, the increasing investment in biotechnology is propelling the growth of the arteriovenous malformations market.

How Is The Arteriovenous Malformations Market Divided Into Its Major Segments?

The arteriovenous malformations market covered in this report is segmented –

1) By Type: True Arteriovenous Malformation, Occult Or Cryptic, Cavernous Malformations, Venous Malformation, Hemangioma, Dural Fistula, Other Types

2) By Diagnosis: Physical examination, Brain Scans, Other Diagnosis

3) By Treatment: Endovascular Embolization, Neurosurgery

4) By Age Group: Adult Patients, Pediatric Patients

5) By End-User: Hospitals And Clinics, Research laboratories, Other End-Users

Subsegments:

1) By True Arteriovenous Malformation: Pial AVMs, Spinal AVMs, Brain AVMs, Extremity AVMs, Visceral AVMs

2) By Occult or Cryptic: Micro-AVMs, Hidden AVMs, Asymptomatic AVMs, Deep-Seated AVMs, Small-Scale AVMs

3) By Cavernous Malformations: Cerebral Cavernous Malformations (CCMs), Spinal Cavernous Malformations, Familial Cavernous Malformations, Solitary Cavernous Malformations, Multiple Cavernous Malformations

4) By Venous Malformation: Superficial Venous Malformations, Deep Venous Malformations, Mixed Venous Malformations, Syndromic Venous Malformations, Blue Rubber Bleb Nevus Syndrome

5) By Hemangioma: Infantile Hemangiomas, Capillary Hemangiomas, Lobular Capillary Hemangiomas, Cavernous Hemangiomas, Compound Hemangiomas

6) By Dural Fistula: Cranial Dural Arteriovenous Fistula (dAVF), Spinal Dural Arteriovenous Fistula, Direct Dural AV Fistula, Indirect Dural AV Fistula, High-Flow Dural Fistula

7) By Other Types: Lymphatic Malformations, Mixed Vascular Malformations, Arteriovenous Aneurysms, Hereditary Hemorrhagic Telangiectasia (HHT)-Associated AVMs, Rare Congenital AVMs

What Major Market Trends Are Driving Changes In The Arteriovenous Malformations Market?

Major companies within the arteriovenous malformations market are concentrating on technological advancements, such as liquid embolic system procedural sets, to improve treatment efficiency and patient outcomes. A liquid embolic system procedural set refers to a pre-assembled, sterile kit containing key components for administering liquid embolic agents to manage vascular abnormalities like arteriovenous malformations (AVMs). For instance, in March 2024, CERENOVUS Inc., a US-based neurovascular care company under Johnson and Johnson MedTech, introduced the TRUFILL n-BCA liquid embolic system procedural set. This new set features two configurations and the necessary accessories for preparing and delivering the n-BCA liquid embolic system within a single sterilized package, thus optimizing procedure preparation for treating cerebral arteriovenous malformations (AVMs).

Who Are The Prominent Organizations Shaping The Arteriovenous Malformations Market?

Major companies operating in the arteriovenous malformations market are Johnson And Johnson Services Inc, Medtronic Plc, Stryker Corporation, Terumo Corporation, Penumbra Inc, Cook Medical LLC, Elekta AB, Merit Medical Systems Inc, Balt LLC, Shape Memory Medical Inc, MicroVention Inc, Cerenovus, Brainlab AG, Boston Scientific Corporation, Abbott Laboratories, B Braun Melsungen AG, Siemens Healthineers AG, GE Healthcare Technologies Inc, Koninklijke Philips NV, Canon Medical Systems Corporation, Toshiba Medical Systems Corporation

Read the full arteriovenous malformations market report here:

https://www.thebusinessresearchcompany.com/report/arteriovenous-malformations-global-market-report

Which Region Is Forecast To Lead The Arteriovenous Malformations Market In Terms Of Market Size?

North America was the largest region in the arteriovenous malformations market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the arteriovenous malformations market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Arteriovenous Malformations Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21888&type=smp

Browse Through More Reports Similar to the Global Arteriovenous Malformations Market 2026, By The Business Research Company

Vascular Imaging Global Market Report

https://www.thebusinessresearchcompany.com/report/vascular-imaging-global-market-report

Giant Cell Arteritis Global Market Report

https://www.thebusinessresearchcompany.com/report/giant-cell-arteritis-global-market-report

Vascular Stent Global Market Report

https://www.thebusinessresearchcompany.com/report/vascular-stent-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Anticipated For The Arteriovenous Malformations Market Over The Period 2026–2030?

The arteriovenous malformations market has witnessed significant expansion in recent times. Its value is forecast to climb from $3.1 billion in 2025 to $3.33 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.3%. This historical upward trend is attributable to breakthroughs in neuroimaging technologies, heightened clinical recognition of AVM conditions, the establishment of more specialized neurosurgical centers, the adoption of endovascular embolization methods, and the growth of neurological services in hospitals.

The arteriovenous malformations market size is anticipated to experience robust expansion over the coming years. It is projected to achieve a value of $4.37 billion by 2030, progressing at a compound annual growth rate (CAGR) of 7.1%. This projected growth throughout the forecast period primarily stems from an escalating demand for accurate diagnostics, increased investments in neurovascular research, a broader embrace of minimally invasive treatments, an intensified focus on customized treatment strategies, and the greater availability of sophisticated interventional devices. Significant patterns expected during this period encompass the growing integration of advanced neuroimaging diagnostics, an increase in the application of minimally invasive endovascular procedures, a heightened emphasis on prompt and precise diagnosis, the broadening of interdisciplinary treatment methodologies, and improved oversight of patient outcomes following treatment.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21888&type=smp

What Drivers Are Expected To Influence The Arteriovenous Malformations Market During The Forecast Period?

The growing demand for minimally invasive procedures is anticipated to propel the arteriovenous malformations market forward. Minimally invasive procedures encompass surgical or therapeutic interventions performed through small incisions or catheter-based methods, aiming to reduce trauma, shorten recovery periods, and lower complications. The increasing preference for these surgeries stems from their quicker recovery times, as smaller incisions cause less tissue damage and accelerate healing. This enables patients to return to their daily routines more rapidly compared to conventional open surgeries, making them a favored option for both patients and healthcare providers. Arteriovenous malformations (AVMs) are well-suited for minimally invasive procedures by allowing advanced techniques such as endovascular embolization, which employs catheters and image-guided interventions to alleviate abnormal blood flow without the necessity of open surgery, leading to reduced risks, shorter recovery times, and improved patient outcomes. For instance, in September 2023, data from the American Society of Plastic Surgeons showed that a total of 25,442,640 cosmetic minimally invasive procedures were performed in the US in 2023, indicating an increase from 23,672,269 procedures in 2022. This reflects a 7% growth in minimally invasive treatments for both genders in 2023. Consequently, the rising demand for minimally invasive procedures is driving the expansion of the arteriovenous malformations market. The increasing investment in biotechnology is projected to stimulate the growth of the arteriovenous malformations market going forward. Biotechnology involves the utilization of biological processes, organisms, or systems to develop products and technologies for healthcare. Enhanced investments in biotechnology are a result of breakthroughs in gene editing technologies like CRISPR, which facilitate precise genetic modifications alongside innovations in medicine. Arteriovenous malformations (AVMs) benefit from biotechnology through advancements in medical imaging, gene therapy, and minimally invasive treatments, leading to biotechnology-derived solutions such as targeted drug delivery, biomaterials for vascular repair, and AI-assisted diagnostics. For instance, in August 2024, according to The BioIndustry Association (BIA), the UK’s life sciences and biotechnology sector recorded its most substantial investment quarter since the pandemic in 2024, securing $2.55 billion in the first two quarters of the year and surpassing the $2.32 billion raised in 2023. Therefore, the increasing investment in biotechnology is propelling the growth of the arteriovenous malformations market.

How Is The Arteriovenous Malformations Market Divided Into Its Major Segments?

The arteriovenous malformations market covered in this report is segmented –

1) By Type: True Arteriovenous Malformation, Occult Or Cryptic, Cavernous Malformations, Venous Malformation, Hemangioma, Dural Fistula, Other Types

2) By Diagnosis: Physical examination, Brain Scans, Other Diagnosis

3) By Treatment: Endovascular Embolization, Neurosurgery

4) By Age Group: Adult Patients, Pediatric Patients

5) By End-User: Hospitals And Clinics, Research laboratories, Other End-Users

Subsegments:

1) By True Arteriovenous Malformation: Pial AVMs, Spinal AVMs, Brain AVMs, Extremity AVMs, Visceral AVMs

2) By Occult or Cryptic: Micro-AVMs, Hidden AVMs, Asymptomatic AVMs, Deep-Seated AVMs, Small-Scale AVMs

3) By Cavernous Malformations: Cerebral Cavernous Malformations (CCMs), Spinal Cavernous Malformations, Familial Cavernous Malformations, Solitary Cavernous Malformations, Multiple Cavernous Malformations

4) By Venous Malformation: Superficial Venous Malformations, Deep Venous Malformations, Mixed Venous Malformations, Syndromic Venous Malformations, Blue Rubber Bleb Nevus Syndrome

5) By Hemangioma: Infantile Hemangiomas, Capillary Hemangiomas, Lobular Capillary Hemangiomas, Cavernous Hemangiomas, Compound Hemangiomas

6) By Dural Fistula: Cranial Dural Arteriovenous Fistula (dAVF), Spinal Dural Arteriovenous Fistula, Direct Dural AV Fistula, Indirect Dural AV Fistula, High-Flow Dural Fistula

7) By Other Types: Lymphatic Malformations, Mixed Vascular Malformations, Arteriovenous Aneurysms, Hereditary Hemorrhagic Telangiectasia (HHT)-Associated AVMs, Rare Congenital AVMs

What Major Market Trends Are Driving Changes In The Arteriovenous Malformations Market?

Major companies within the arteriovenous malformations market are concentrating on technological advancements, such as liquid embolic system procedural sets, to improve treatment efficiency and patient outcomes. A liquid embolic system procedural set refers to a pre-assembled, sterile kit containing key components for administering liquid embolic agents to manage vascular abnormalities like arteriovenous malformations (AVMs). For instance, in March 2024, CERENOVUS Inc., a US-based neurovascular care company under Johnson and Johnson MedTech, introduced the TRUFILL n-BCA liquid embolic system procedural set. This new set features two configurations and the necessary accessories for preparing and delivering the n-BCA liquid embolic system within a single sterilized package, thus optimizing procedure preparation for treating cerebral arteriovenous malformations (AVMs).

Who Are The Prominent Organizations Shaping The Arteriovenous Malformations Market?

Major companies operating in the arteriovenous malformations market are Johnson And Johnson Services Inc, Medtronic Plc, Stryker Corporation, Terumo Corporation, Penumbra Inc, Cook Medical LLC, Elekta AB, Merit Medical Systems Inc, Balt LLC, Shape Memory Medical Inc, MicroVention Inc, Cerenovus, Brainlab AG, Boston Scientific Corporation, Abbott Laboratories, B Braun Melsungen AG, Siemens Healthineers AG, GE Healthcare Technologies Inc, Koninklijke Philips NV, Canon Medical Systems Corporation, Toshiba Medical Systems Corporation

Read the full arteriovenous malformations market report here:

https://www.thebusinessresearchcompany.com/report/arteriovenous-malformations-global-market-report

Which Region Is Forecast To Lead The Arteriovenous Malformations Market In Terms Of Market Size?

North America was the largest region in the arteriovenous malformations market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the arteriovenous malformations market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Arteriovenous Malformations Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21888&type=smp

Browse Through More Reports Similar to the Global Arteriovenous Malformations Market 2026, By The Business Research Company

Vascular Imaging Global Market Report

https://www.thebusinessresearchcompany.com/report/vascular-imaging-global-market-report

Giant Cell Arteritis Global Market Report

https://www.thebusinessresearchcompany.com/report/giant-cell-arteritis-global-market-report

Vascular Stent Global Market Report

https://www.thebusinessresearchcompany.com/report/vascular-stent-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Anticipated For The Arteriovenous Malformations Market Over The Period 2026–2030?

The arteriovenous malformations market has witnessed significant expansion in recent times. Its value is forecast to climb from $3.1 billion in 2025 to $3.33 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.3%. This historical upward trend is attributable to breakthroughs in neuroimaging technologies, heightened clinical recognition of AVM conditions, the establishment of more specialized neurosurgical centers, the adoption of endovascular embolization methods, and the growth of neurological services in hospitals.

The arteriovenous malformations market size is anticipated to experience robust expansion over the coming years. It is projected to achieve a value of $4.37 billion by 2030, progressing at a compound annual growth rate (CAGR) of 7.1%. This projected growth throughout the forecast period primarily stems from an escalating demand for accurate diagnostics, increased investments in neurovascular research, a broader embrace of minimally invasive treatments, an intensified focus on customized treatment strategies, and the greater availability of sophisticated interventional devices. Significant patterns expected during this period encompass the growing integration of advanced neuroimaging diagnostics, an increase in the application of minimally invasive endovascular procedures, a heightened emphasis on prompt and precise diagnosis, the broadening of interdisciplinary treatment methodologies, and improved oversight of patient outcomes following treatment.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21888&type=smp

What Drivers Are Expected To Influence The Arteriovenous Malformations Market During The Forecast Period?

The growing demand for minimally invasive procedures is anticipated to propel the arteriovenous malformations market forward. Minimally invasive procedures encompass surgical or therapeutic interventions performed through small incisions or catheter-based methods, aiming to reduce trauma, shorten recovery periods, and lower complications. The increasing preference for these surgeries stems from their quicker recovery times, as smaller incisions cause less tissue damage and accelerate healing. This enables patients to return to their daily routines more rapidly compared to conventional open surgeries, making them a favored option for both patients and healthcare providers. Arteriovenous malformations (AVMs) are well-suited for minimally invasive procedures by allowing advanced techniques such as endovascular embolization, which employs catheters and image-guided interventions to alleviate abnormal blood flow without the necessity of open surgery, leading to reduced risks, shorter recovery times, and improved patient outcomes. For instance, in September 2023, data from the American Society of Plastic Surgeons showed that a total of 25,442,640 cosmetic minimally invasive procedures were performed in the US in 2023, indicating an increase from 23,672,269 procedures in 2022. This reflects a 7% growth in minimally invasive treatments for both genders in 2023. Consequently, the rising demand for minimally invasive procedures is driving the expansion of the arteriovenous malformations market. The increasing investment in biotechnology is projected to stimulate the growth of the arteriovenous malformations market going forward. Biotechnology involves the utilization of biological processes, organisms, or systems to develop products and technologies for healthcare. Enhanced investments in biotechnology are a result of breakthroughs in gene editing technologies like CRISPR, which facilitate precise genetic modifications alongside innovations in medicine. Arteriovenous malformations (AVMs) benefit from biotechnology through advancements in medical imaging, gene therapy, and minimally invasive treatments, leading to biotechnology-derived solutions such as targeted drug delivery, biomaterials for vascular repair, and AI-assisted diagnostics. For instance, in August 2024, according to The BioIndustry Association (BIA), the UK’s life sciences and biotechnology sector recorded its most substantial investment quarter since the pandemic in 2024, securing $2.55 billion in the first two quarters of the year and surpassing the $2.32 billion raised in 2023. Therefore, the increasing investment in biotechnology is propelling the growth of the arteriovenous malformations market.

How Is The Arteriovenous Malformations Market Divided Into Its Major Segments?

The arteriovenous malformations market covered in this report is segmented –

1) By Type: True Arteriovenous Malformation, Occult Or Cryptic, Cavernous Malformations, Venous Malformation, Hemangioma, Dural Fistula, Other Types

2) By Diagnosis: Physical examination, Brain Scans, Other Diagnosis

3) By Treatment: Endovascular Embolization, Neurosurgery

4) By Age Group: Adult Patients, Pediatric Patients

5) By End-User: Hospitals And Clinics, Research laboratories, Other End-Users

Subsegments:

1) By True Arteriovenous Malformation: Pial AVMs, Spinal AVMs, Brain AVMs, Extremity AVMs, Visceral AVMs

2) By Occult or Cryptic: Micro-AVMs, Hidden AVMs, Asymptomatic AVMs, Deep-Seated AVMs, Small-Scale AVMs

3) By Cavernous Malformations: Cerebral Cavernous Malformations (CCMs), Spinal Cavernous Malformations, Familial Cavernous Malformations, Solitary Cavernous Malformations, Multiple Cavernous Malformations

4) By Venous Malformation: Superficial Venous Malformations, Deep Venous Malformations, Mixed Venous Malformations, Syndromic Venous Malformations, Blue Rubber Bleb Nevus Syndrome

5) By Hemangioma: Infantile Hemangiomas, Capillary Hemangiomas, Lobular Capillary Hemangiomas, Cavernous Hemangiomas, Compound Hemangiomas

6) By Dural Fistula: Cranial Dural Arteriovenous Fistula (dAVF), Spinal Dural Arteriovenous Fistula, Direct Dural AV Fistula, Indirect Dural AV Fistula, High-Flow Dural Fistula

7) By Other Types: Lymphatic Malformations, Mixed Vascular Malformations, Arteriovenous Aneurysms, Hereditary Hemorrhagic Telangiectasia (HHT)-Associated AVMs, Rare Congenital AVMs

What Major Market Trends Are Driving Changes In The Arteriovenous Malformations Market?

Major companies within the arteriovenous malformations market are concentrating on technological advancements, such as liquid embolic system procedural sets, to improve treatment efficiency and patient outcomes. A liquid embolic system procedural set refers to a pre-assembled, sterile kit containing key components for administering liquid embolic agents to manage vascular abnormalities like arteriovenous malformations (AVMs). For instance, in March 2024, CERENOVUS Inc., a US-based neurovascular care company under Johnson and Johnson MedTech, introduced the TRUFILL n-BCA liquid embolic system procedural set. This new set features two configurations and the necessary accessories for preparing and delivering the n-BCA liquid embolic system within a single sterilized package, thus optimizing procedure preparation for treating cerebral arteriovenous malformations (AVMs).

Who Are The Prominent Organizations Shaping The Arteriovenous Malformations Market?

Major companies operating in the arteriovenous malformations market are Johnson And Johnson Services Inc, Medtronic Plc, Stryker Corporation, Terumo Corporation, Penumbra Inc, Cook Medical LLC, Elekta AB, Merit Medical Systems Inc, Balt LLC, Shape Memory Medical Inc, MicroVention Inc, Cerenovus, Brainlab AG, Boston Scientific Corporation, Abbott Laboratories, B Braun Melsungen AG, Siemens Healthineers AG, GE Healthcare Technologies Inc, Koninklijke Philips NV, Canon Medical Systems Corporation, Toshiba Medical Systems Corporation

Read the full arteriovenous malformations market report here:

https://www.thebusinessresearchcompany.com/report/arteriovenous-malformations-global-market-report

Which Region Is Forecast To Lead The Arteriovenous Malformations Market In Terms Of Market Size?

North America was the largest region in the arteriovenous malformations market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the arteriovenous malformations market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Arteriovenous Malformations Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21888&type=smp

Browse Through More Reports Similar to the Global Arteriovenous Malformations Market 2026, By The Business Research Company

Vascular Imaging Global Market Report

https://www.thebusinessresearchcompany.com/report/vascular-imaging-global-market-report

Giant Cell Arteritis Global Market Report

https://www.thebusinessresearchcompany.com/report/giant-cell-arteritis-global-market-report

Vascular Stent Global Market Report

https://www.thebusinessresearchcompany.com/report/vascular-stent-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model